Biolife solutions announces additional delay in filing of annual report on form 10-k

Bothell, wash., march 17, 2022 /prnewswire/ -- biolife solutions, inc. (nasdaq: blfs) ("biolife" or the "company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (cgt) and the broader biopharma markets, announced today an additional delay in the filing of its annual report on form 10-k for the year ended december 31, 2021 (the "form 10-k").
BLFS Ratings Summary
BLFS Quant Ranking